Veeva Systems || OpenData
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!
Enquire now and stand a chance to win exclusive gifts!

Novel APL-106 (uproleselan) Discovered for the Treatment of Acute Myeloid Leukemia

Apollomics, Inc discovered novel APL-106 (uproleselan) for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) in China.

AML is an aggressive disease and relapsed/refractory having an extremely poor prognosis in patients.

AML is a blood and bone marrow cancer. It is an aggressive disease which causes the bone marrow to produce immature cells which cannot carry out their normal function and thus results in developing into leukemic white blood cells called myeloblasts. In addition, every year 20,000 new cases of AML generate.

(APL-106) is a late clinical stage first-in-class, targeted inhibitor of E-selectin. In September 2020, the NMPA CDE has granted Investigational New Drug (IND) approval for APL-106 enabling the initiation of a Phase 1 pharmacokinetics (PK) and tolerability study and includes acceptance of a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory AML

APL-106 (uproleselan) has been granted Breakthrough Therapy Designation for the treatment of Acute Myeloid Leukemia in China.

Latest Issue
Get instant
access to our latest e-book
Lonza Capsugel® Zephyr™ Dry-Powder Inhalation Capsule Portfolio Kerry || Webinar || Regulatory Considerations Regarding IR Film Coating Post-Approval Changes Meco - 90 years Medical Fair Thailand 2022